Taiwan Registry of Hypertrophic Cardiomyopathy (THIC) Research Synopsis.

The article discusses a newly launched clinical trial in Taiwan called the Taiwan Registry of Hypertrophic Cardiomyopathy (THIC) Research Synopsis. The trial aims to evaluate the clinical, genetic, and biochemical features, prevalence, and natural course of hypertrophic cardiomyopathy (HCM) and related rare diseases such as Fabry disease in Taiwan. HCM is characterized by left ventricular hypertrophy and can present various symptoms including arrhythmia and heart failure. The trial will also explore the specific signs of Fabry disease in Taiwan. The trial is currently recruiting participants and is expected to be completed by December 2027. [Extracted from the article]